首页> 美国卫生研究院文献>Respiratory Medicine Case Reports >Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report
【2h】

Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report

机译:通过反复基因测试在具有表皮生长因子受体突变的肺腺癌患者中成功序贯治疗小细胞癌转化和EGFR-T790M突变导致的难治性肿瘤:一例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

NSCLC patients with EGFR mutations respond to EGFR-TKIs; however, the management of refractory tumors to EGFR-TKIs remains unclear. We demonstrated that repeated genetic testing might be useful for detecting resistance mechanisms as well as for decision-making in EGFR mutated NSCLC patients, following the emergence of resistance to the initial EGFR-TKIs.A 69-year-old man was diagnosed with lung adenocarcinoma with an EGFR exon 19 deletion. After tumor re-growth treated with erlotinib and chemotherapy, he was diagnosed with an SCLC transformation and administered chemotherapy to treat the SCLC. After the resistance of chemotherapy, the EGFR-T790M mutation by liquid biopsy was detected and treated him with osimertinib, which resulted in a clinical response.
机译:EGFR突变的NSCLC患者对EGFR-TKI有反应;然而,对于EGFR-TKIs的难治性肿瘤的治疗仍不清楚。我们证明了对最初的EGFR-TKIs产生抗药性之后,重复的基因测试可能对检测EGFR突变的NSCLC患者的抗药性机制以及决策具有帮助.69岁的男性被诊断患有肺腺癌。 EGFR外显子19缺失。厄洛替尼和化疗使肿瘤重新生长后,他被诊断患有SCLC转化并进行了化疗以治疗SCLC。化疗耐药后,通过液体活检检测到EGFR-T790M突变,并用奥西替尼治疗他,从而产生临床反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号